Sonnet's son-1010 demonstrates a strong safety profile in combination with atezolizumab for treatment of platinum-resistant ovarian cancer, including a partial response at the highest dose

Topline safety data in sb221 study suggest clinical benefit of son-1010 in combination with atezolizumab (tecentriq ® )
SONN Ratings Summary
SONN Quant Ranking